

Paulo C Rodriguez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1187619/publications.pdf>

Version: 2024-02-01

142
papers

15,855
citations

38660

50
h-index

25716

108
g-index

145
all docs

145
docs citations

145
times ranked

17896
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine. <i>Cancer Immunology Research</i> , 2022, 10, 108-125.	1.6	8
2	TGF- β -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. <i>Immunity</i> , 2022, 55, 115-128.e9.	6.6	62
3	DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets. <i>Biology</i> , 2022, 11, 260.	1.3	5
4	A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. <i>Neuro-Oncology</i> , 2022, 24, 1673-1686.	0.6	6
5	Increased inflammatory low-density neutrophils in severe obesity and effect of bariatric surgery: Results from case-control and prospective cohort studies. <i>EBioMedicine</i> , 2022, 77, 103910.	2.7	10
6	Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. <i>Cancer Discovery</i> , 2022, 12, 1294-1313.	7.7	18
7	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. <i>Cancer Research</i> , 2022, 82, 859-871.	0.4	21
8	Carbon Monoxide Activates PERK-Regulated Autophagy to Induce Immunometabolic Reprogramming and Boost Antitumor T-cell Function. <i>Cancer Research</i> , 2022, 82, 1969-1990.	0.4	21
9	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T α cells. <i>Cancer Cell</i> , 2022, 40, 545-557.e13.	7.7	53
10	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 2131-2146.	3.2	36
11	Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells. <i>Cancer Cell</i> , 2022, 40, 597-599.	7.7	4
12	Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity. <i>Trends in Cancer</i> , 2022, 8, 930-943.	3.8	27
13	MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. <i>Nature Immunology</i> , 2021, 22, 53-66.	7.0	95
14	IgA transcytosis and antigen recognition govern ovarian cancer immunity. <i>Nature</i> , 2021, 591, 464-470.	13.7	99
15	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	6
16	Targeted Therapy Given after Anti- α PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. <i>Cancer Immunology Research</i> , 2021, 9, 554-567.	1.6	15
17	Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4109-4125.	3.2	65
18	Tumor-related stress regulates functional plasticity of MDSCs. <i>Cellular Immunology</i> , 2021, 363, 104312.	1.4	10

#	ARTICLE	IF	CITATIONS
19	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	0.6	137
20	The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. <i>Immunity</i> , 2021, 54, 1154-1167.e7.	6.6	109
21	Innate immune cells in the tumor microenvironment. <i>Cancer Cell</i> , 2021, 39, 725-729.	7.7	55
22	Cavity macrophages stop anti-tumor T ^H cells. <i>Cancer Cell</i> , 2021, 39, 900-902.	7.7	2
23	OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, ii17-ii17.	0.4	0
24	LMD-03. Single cell analysis reveals how therapy remodels the tumor microenvironment in melanoma CNS metastases and uncovers a novel predictor of improved survival. <i>Neuro-Oncology Advances</i> , 2021, 3, iii7-iii8.	0.4	0
25	Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T ^H cell immunity. <i>Immunity</i> , 2021, 54, 2354-2371.e8.	6.6	34
26	BTN3A1 governs antitumor responses by coordinating I α 1 ^{hi} and I β 1 ^{hi} T cells. <i>Science</i> , 2020, 369, 942-949.	6.0	83
27	Kindlin-3 gives patrolling monocytes a strong grip. <i>Journal of Leukocyte Biology</i> , 2020, 107, 879-881.	1.5	0
28	CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint. <i>Nature Communications</i> , 2020, 11, 515.	5.8	117
29	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. <i>Immunity</i> , 2020, 52, 668-682.e7.	6.6	107
30	c-Maf: a bad influence in the education of macrophages. <i>Journal of Clinical Investigation</i> , 2020, 130, 1629-1631.	3.9	11
31	Abstract 4517: Targeting Notch1 via adenosine A2A receptor to modulate tumor immunity. , 2020, , .		0
32	Abstract 5511: Frontline therapy with anti-PD1 enhances the durability of combination targeted therapy in NRAS-mutant melanoma. , 2020, , .		0
33	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2019, 79, 5034-5047.	0.4	37
34	Polyphenol-rich extract induces apoptosis with immunogenic markers in melanoma cells through the ER stress-associated kinase PERK. <i>Cell Death Discovery</i> , 2019, 5, 134.	2.0	30
35	ER stress-induced mediator C/EBP homologous protein thwarts effector T ^H cell activity in tumors through T-bet repression. <i>Nature Communications</i> , 2019, 10, 1280.	5.8	83
36	Adenosine A2A Receptor Stimulation Inhibits TCR-Induced Notch1 Activation in CD8 ⁺ T-Cells. <i>Frontiers in Immunology</i> , 2019, 10, 162.	2.2	46

#	ARTICLE	IF	CITATIONS
37	Abstract 3275: Inhibition of ER-stress factor C/EBP homologous protein (Chop) with LNAplus [®] , [®] antisense-oligonucleotides to improve immunotherapy of cancer. , 2019, , .		0
38	Abstract 3275: Inhibition of ER-stress factor C/EBP homologous protein (Chop) with LNAplus [®] , [®] antisense-oligonucleotides to improve immunotherapy of cancer. , 2019, , .		0
39	Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c+CD103+ Monocytic Antigen-Presenting Cells in Tumors. <i>Immunity</i> , 2018, 48, 91-106.e6.	6.6	95
40	The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. <i>Cellular and Molecular Immunology</i> , 2018, 15, 421-427.	4.8	26
41	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2887.	2.2	19
42	Notch Signaling: A Pivot Regulator of Adaptive and Innate Immunity. , 2018, , 127-151.		0
43	Arginase 1 promotes retinal neurovascular protection from ischemia through suppression of macrophage inflammatory responses. <i>Cell Death and Disease</i> , 2018, 9, 1001.	2.7	52
44	IRE1 [±] XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. <i>Nature</i> , 2018, 562, 423-428.	13.7	252
45	Arginase: A Multifaceted Enzyme Important in Health and Disease. <i>Physiological Reviews</i> , 2018, 98, 641-665.	13.1	303
46	Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses. <i>Frontiers in Immunology</i> , 2018, 9, 1288.	2.2	38
47	Abstract 4717: MAP kinase inhibition induces metabolic reprogramming in T-cells leading to induction of stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 antibody. , 2018, , .		0
48	Differential PI3K ^Î Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy. <i>Cancer Research</i> , 2017, 77, 1892-1904.	0.4	84
49	Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer. , 2017, 5, 5.		67
50	IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1049-1058.	2.0	32
51	Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. <i>Cancer Prevention Research</i> , 2017, 10, 377-388.	0.7	64
52	Fuelling the mechanisms of asthma: Increased fatty acid oxidation in inflammatory immune cells may represent a novel therapeutic target. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1170-1184.	1.4	28
53	Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by <i>Ex Vivo</i> PI3K ^Î Inhibition. <i>Cancer Research</i> , 2017, 77, 4135-4145.	0.4	61
54	Energy metabolic pathways control the fate and function of myeloid immune cells. <i>Journal of Leukocyte Biology</i> , 2017, 102, 369-380.	1.5	49

#	ARTICLE	IF	CITATIONS
55	Endoplasmic reticulum stress regulates tumor growth and anti-tumor immunity: a promising opportunity for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1069-1078.	2.0	80
56	Canonical NF κ B signaling in myeloid cells is required for the glioblastoma growth. <i>Scientific Reports</i> , 2017, 7, 13754.	1.6	36
57	ABC294640, A Novel Sphingosine Kinase 2 Inhibitor, Induces Oncogenic Virus-Infected Cell Autophagic Death and Represses Tumor Growth. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2724-2734.	1.9	25
58	Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance. <i>Cancer Research</i> , 2017, 77, 5628-5638.	0.4	70
59	Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. <i>Oncolmunology</i> , 2017, 6, e1344804.	2.1	209
60	Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 93.	2.2	197
61	Effective antitumor peptide vaccines can induce severe autoimmune pathology. <i>Oncotarget</i> , 2017, 8, 70317-70331.	0.8	12
62	Abstract 3992: Immune regulation of disseminated tumor cell clearance versus metastatic growth. , 2017, , .		0
63	Abstract 5807: Disseminated tumor cell clearance by the immune system. , 2017, , .		0
64	Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer. <i>Oncolmunology</i> , 2016, 5, e1200771.	2.1	45
65	Editorial: A matter of survival: HMGB1 regulates autophagy in tumor MDSC. <i>Journal of Leukocyte Biology</i> , 2016, 100, 447-449.	1.5	1
66	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , 2016, 7, 12150.	5.8	2,076
67	T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy. <i>Oncotarget</i> , 2016, 7, 17565-17578.	0.8	13
68	Soluble Mediators of Immune Suppression in the Tumor Microenvironment. , 2016, , 526-533.		0
69	Abstract LB-271: Targeting fatty acid metabolism regulates the immunosuppressive activity of myeloid-derived suppressor cells. , 2016, , .		0
70	Abstract LB-077: T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy. , 2016, , .		0
71	PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. <i>Clinical Science</i> , 2015, 129, 951-962.	1.8	35
72	Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. , 2015, 3, .		5

#	ARTICLE	IF	CITATIONS
73	PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function. <i>Journal of Translational Medicine</i> , 2015, 13, 225.	1.8	39
74	Antigen-specific T cells conditioned with MDSC display a surprising increased anti-tumor activity after adoptive T cell-based immunotherapy. , 2015, 3, P413.		0
75	DNA-dependent protein kinase inhibition blocks asthma in mice and modulates human endothelial and CD4+ T-cell function without causing severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 425-440.	1.5	29
76	Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. <i>Cancer Immunology Research</i> , 2015, 3, 1236-1247.	1.6	387
77	<scp>l</scp>-Arginine Depletion Blunts Antitumor T-cell Responses by Inducing Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2015, 75, 275-283.	0.4	209
78	DNA-Dependent Protein Kinase Inhibition Blocks Asthma in Mice and Modulates Human Endothelial and CD4 + T Cell Function Without Causing SCID. <i>FASEB Journal</i> , 2015, 29, 626.6.	0.2	0
79	PARP Inhibition Blocks Asthma Manifestation in a Chronic House Dust Mite (HDM) Asthma Model and Differentially Modulates Human CD4 + T cell Function. <i>FASEB Journal</i> , 2015, 29, 1027.5.	0.2	0
80	PARADOXICAL ROLES OF PARPá€ł IN COLON INFLAMMATION AND TUMORIGENESIS. <i>FASEB Journal</i> , 2015, 29, 629.11.	0.2	1
81	Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4024-32.	3.3	103
82	Expression of Arginase I in Myeloid Cells Limits Control of Residual Disease after Radiation Therapy of Tumors in Mice. <i>Radiation Research</i> , 2014, 182, 182-190.	0.7	35
83	Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 154-164.	1.9	52
84	Subpopulations of myeloidá€łderived suppressor cells impair T cell responses through independent nitric oxideá€łrelated pathways. <i>International Journal of Cancer</i> , 2014, 134, 2853-2864.	2.3	230
85	Arginine Metabolism, a Major Pathway for the Suppressive Function of Myeloid-Derived Suppressor Cells. , 2014, , 369-386.		1
86	Arginase I levels are decreased in the plasma of pediatric patients with atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 113, 271-275.	0.5	9
87	The Stress-Response Sensor Chop Regulates the Function and Accumulation of Myeloid-Derived Suppressor Cells in Tumors. <i>Immunity</i> , 2014, 41, 389-401.	6.6	200
88	Rescue of Notch-1 Signaling in Antigen-Specific CD8+ T Cells Overcomes Tumor-Induced T-cell Suppression and Enhances Immunotherapy in Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 800-811.	1.6	71
89	Tumor derived stress triggers C/EBPá€ł2 homologous protein (Chop) expression in myeloid derived suppressor cells (MDSC) and mediates immunosuppressive activity. , 2014, 2, .		0
90	The Central Role of Arginine Catabolism in T-Cell Dysfunction and Increased Susceptibility to Infection After Physical Injury. <i>Annals of Surgery</i> , 2014, 259, 171-178.	2.1	92

#	ARTICLE	IF	CITATIONS
91	Effects of cigarette smoke extract on primary activated T cells. Cellular Immunology, 2013, 282, 38-43.	1.4	37
92	Corneal neovascularization: a review of the molecular biology and current therapies. Expert Review of Ophthalmology, 2013, 8, 167-189.	0.3	9
93	The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model. Antiviral Research, 2013, 100, 14-19.	1.9	2
94	Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia. Leukemia, 2013, 27, 569-577.	3.3	44
95	Modulation of T cell function through L-arginine metabolism: a new therapy from an old enemy. , 2013, 1, O10.		1
96	Independent mechanisms of T cell-suppression by subpopulations of myeloid-derived suppressor cells (MDSC) in tumor-bearing hosts. , 2013, 1, P193.		0
97	Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network. Cancer Research, 2013, 73, 1668-1675.	0.4	64
98	Minocycline Blocks Asthma-associated Inflammation in Part by Interfering with the T Cell Receptor-Nuclear Factor κ B-GATA-3-IL-4 Axis without a Prominent Effect on Poly(ADP-ribose) Polymerase. Journal of Biological Chemistry, 2013, 288, 1458-1468.	1.6	21
99	Polycyclic aromatic hydrocarbons-induced ROS accumulation enhances mutagenic potential of T antigen from human polyomavirus JC. Journal of Cellular Physiology, 2013, 228, 2127-2138.	2.0	33
100	P-189 Pegylated Arginase-1 Mediates Suppression of Mouse and Human CD4 T Cells. Inflammatory Bowel Diseases, 2013, 19, S101.	0.9	1
101	Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives. , 2013, , 315-333.		1
102	MINOCYCLINE BLOCKS ALLERGEN-INDUCED EOSINOPHILIA AND PRODUCTION OF TH2 CYTOKINES AND IGE BY INTERFERING WITH THE T CELL RECEPTOR- κ B-GATA-3-INTERLEUKIN (IL)-4 AXIS IN A MURINE ASTHMA MODEL WITHOUT AN EFFECT ON PARP. FASEB Journal, 2013, 27, 254.2.		0
103	Olaparib, a PARP inhibitor approved for human testing, prevents allergen-induced airway inflammation and hyperresponsiveness in a mouse model of asthma and reduces proliferation of human CD3/C28-stimulated CD4+ T cells. FASEB Journal, 2013, 27, 1107.1.	0.2	1
104	Modulation Of T Cell Function Through L-Arginine Metabolism: A New Therapy From An Old Enemy. Blood, 2013, 122, 1039-1039.	0.6	0
105	Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives. Immunological Investigations, 2012, 41, 614-634.	1.0	238
106	IL-7R α deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. Cell Death and Differentiation, 2012, 19, 1139-1151.	5.0	18
107	Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis. American Journal of Hematology, 2012, 87, 969-976.	2.0	21
108	Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and Therapeutic Perspectives. , 2012, , 319-334.		0

#	ARTICLE	IF	CITATIONS
109	L-arginine depletion by PEG-arginase I, a new potential therapy for acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2012, 30, 6580-6580.	0.8	0
110	Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood, 2010, 115, 5214-5221.	0.6	84
111	Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood, 2010, 116, 5738-5747.	0.6	384
112	Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. Cancer Research, 2010, 70, 68-77.	0.4	748
113	Requirement for Inducible Nitric Oxide Synthase in Chronic Allergen Exposure-Induced Pulmonary Fibrosis but Not Inflammation. Journal of Immunology, 2010, 185, 3076-3085.	0.4	50
114	Arginine Deprivation Regulates Cyclin D3 mRNA Stability in Human T Cells by Controlling HuR Expression. Journal of Immunology, 2010, 185, 5198-5204.	0.4	77
115	Requirement for iNOS in chronic allergen exposure-induced pulmonary fibrosis but not inflammation or mucus production: Specific implications of TGF- β 1, TIMP-2, and arginase-2 expression. FASEB Journal, 2010, 24, 31.7.	0.2	0
116	Bone Marrow Myeloid-Derived Suppressor Cells (MDSC) Inhibit Graft Versus Host Disease (GVHD) Via An Arginase-1 Dependant Mechanism That Is Upregulated by IL-13. Blood, 2010, 116, 241-241.	0.6	0
117	Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via Arginine Metabolism. Cancer Research, 2009, 69, 3086-3094.	0.4	237
118	Arginase-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes. Cancer Research, 2009, 69, 1553-1560.	0.4	697
119	Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological Reviews, 2008, 222, 180-191.	2.8	591
120	TLR9 engagement on CD4 T lymphocytes represses γ -radiation-induced apoptosis through activation of checkpoint kinase response elements. Blood, 2008, 111, 2704-2713.	0.6	41
121	Tumors induce regulatory dendritic cells that suppress CD8+ T cell antitumor immunity. FASEB Journal, 2008, 22, 1078.4.	0.2	0
122	Arginine Availability Regulates T-Cell Function in Cancer. , 2008, , 219-233.		0
123	Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 721s-726s.	3.2	417
124	l-arginine availability regulates T-lymphocyte cell-cycle progression. Blood, 2007, 109, 1568-1573.	0.6	732
125	T cell dysfunction in cancer: Role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Seminars in Cancer Biology, 2006, 16, 66-72.	4.3	65
126	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Journal of Experimental Medicine, 2006, 203, 871-881.	4.2	638

#	ARTICLE	IF	CITATIONS
127	Mechanisms of Tumor Evasion. , 2005, 123, 61-88.		56
128	Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13058-13063.	3.3	164
129	Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion. Cancer Research, 2005, 65, 3044-3048.	0.4	750
130	Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. Journal of Experimental Medicine, 2005, 202, 931-939.	4.2	521
131	Citrulline Can Preserve Proliferation and Prevent the Loss of CD3 ζ Chain Under Conditions of Low Arginine. Journal of Parenteral and Enteral Nutrition, 2004, 28, 423-430.	1.3	52
132	Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses. Cancer Research, 2004, 64, 5839-5849.	0.4	1,023
133	<i>Helicobacter pylori</i> Arginase Inhibits T Cell Proliferation and Reduces the Expression of the TCR ζ -Chain (CD3 ζ). Journal of Immunology, 2004, 173, 586-593.	0.4	115
134	l-Arginine modulates CD3 ζ expression and T cell function in activated human T lymphocytes. Cellular Immunology, 2004, 232, 21-31.	1.4	185
135	Immune Defects in T Cells From Cancer Patients. , 2004, , 35-48.		1
136	Arginine Consumption by Macrophages Modulates the Expression of CD3 ζ Chain in T Lymphocytes. Journal of Immunology, 2003, 171, 1232-1239.	0.4	430
137	Mechanisms of tumor evasion from the immune response. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 351-364.	0.5	29
138	Regulation of T Cell Receptor CD3 ζ Chain Expression by l-Arginine. Journal of Biological Chemistry, 2002, 277, 21123-21129.	1.6	407
139	Detection of alloantibodies against non-HLA antigens in kidney transplantation by flow cytometry. Clinical Transplantation, 2000, 14, 472-478.	0.8	16
140	Detection of allo- and autoantibodies in kidney transplantation by flow cytometry. Transplantation Proceedings, 1999, 31, 282-284.	0.3	4
141	SATB1 Expression Governs Follicular Helper T-cell-Triggered Tertiary Lymphoid Structure Assembly. SSRN Electronic Journal, 0, , .	0.4	0
142	Ovarian Cancer Immunogenicity is Governed by a Narrow Subset of Progenitor Tissue-Resident Memory T-Cells. SSRN Electronic Journal, 0, , .	0.4	0